CO2019014028A2 - Posologías para la administración de análogos de péptido de tipo glucagon-2 (glp-2) - Google Patents
Posologías para la administración de análogos de péptido de tipo glucagon-2 (glp-2)Info
- Publication number
- CO2019014028A2 CO2019014028A2 CONC2019/0014028A CO2019014028A CO2019014028A2 CO 2019014028 A2 CO2019014028 A2 CO 2019014028A2 CO 2019014028 A CO2019014028 A CO 2019014028A CO 2019014028 A2 CO2019014028 A2 CO 2019014028A2
- Authority
- CO
- Colombia
- Prior art keywords
- glp
- administration
- glucagon
- treatment
- dosage
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 abstract 4
- 108060003199 Glucagon Proteins 0.000 abstract 1
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 abstract 1
- 102100040918 Pro-glucagon Human genes 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 abstract 1
- 210000000936 intestine Anatomy 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se desvelan posologías para la administración de análogos de péptido de glucagón 2 (GLP-2) y su uso médico, por ejemplo, en el tratamiento y/o prevención de trastornos relacionados con el estómago y el intestino y para mejorar los efectos secundarios de quimioterapia y radioterapia. Se describen posologías para la administración de análogos de péptido de tipo glucagón 2 (GLP-2) para inducir el crecimiento longitudinal de los intestinos, por ejemplo, para el tratamiento de pacientes con síndrome de intestino pequeño (SBS). Se describen también los usos médicos para ajustar el volumen del soporte parenteral (PS) proporcionados a los sujetos que reciben tratamiento con análogos de GLP-2 en respuesta al tratamiento y a los algoritmos para determinar los cambios de volumen PS.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1709643.9A GB201709643D0 (en) | 2017-06-16 | 2017-06-16 | Dosage regimes for the administration of glucagon-like-peptide-2 (GLP-2) analogues |
| GBGB1714203.5A GB201714203D0 (en) | 2017-09-05 | 2017-09-05 | Dosage regimes for the administration of Glucagon-Like Peptide-2(GLP-2)Analogues |
| GBGB1800873.0A GB201800873D0 (en) | 2018-01-19 | 2018-01-19 | Dosage regimes for the administration of glucagon-like-peptide-2 (GLP-2) analogues |
| PCT/EP2018/065951 WO2018229252A1 (en) | 2017-06-16 | 2018-06-15 | Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2019014028A2 true CO2019014028A2 (es) | 2020-04-01 |
Family
ID=62748940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2019/0014028A CO2019014028A2 (es) | 2017-06-16 | 2019-12-12 | Posologías para la administración de análogos de péptido de tipo glucagon-2 (glp-2) |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20200000883A1 (es) |
| EP (3) | EP3638291B1 (es) |
| JP (2) | JP7200238B2 (es) |
| KR (2) | KR20230035677A (es) |
| CN (2) | CN111032072A (es) |
| AU (2) | AU2018285580B2 (es) |
| BR (1) | BR112019026711A2 (es) |
| CA (1) | CA3066523A1 (es) |
| CL (1) | CL2019003660A1 (es) |
| CO (1) | CO2019014028A2 (es) |
| DK (2) | DK3638291T3 (es) |
| ES (1) | ES2894629T3 (es) |
| IL (2) | IL271245B2 (es) |
| MX (2) | MX2019015054A (es) |
| PE (1) | PE20200678A1 (es) |
| SG (1) | SG11201912161SA (es) |
| TW (1) | TWI791539B (es) |
| WO (1) | WO2018229252A1 (es) |
| ZA (1) | ZA201908355B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4041722A4 (en) | 2019-10-07 | 2023-12-13 | Kallyope, Inc. | GPR119 AGONISTS |
| CA3178994A1 (en) | 2020-05-19 | 2021-11-25 | Iyassu Sebhat | Ampk activators |
| CN111560061A (zh) * | 2020-05-26 | 2020-08-21 | 成都圣诺生物制药有限公司 | 一种Gelpaglutide的制备方法 |
| JP2023531726A (ja) | 2020-06-26 | 2023-07-25 | キャリーオペ，インク． | Ａｍｐｋアクチベーター |
| AU2021402687A1 (en) | 2020-12-16 | 2023-06-22 | Zealand Pharma A/S | Use of glp-2 analogues in patients with renal insufficiency |
| CN118055757A (zh) | 2021-09-10 | 2024-05-17 | 西兰制药公司 | 用于配制包含胰高血糖素样肽-2（glp-2）类似物的组合物的方法 |
| EP4453017A1 (en) | 2021-12-23 | 2024-10-30 | Zealand Pharma A/S | Processes for synthesizing glucagon-like-peptide 2 (glp-2) analogues |
| WO2023132609A1 (ko) * | 2022-01-05 | 2023-07-13 | 주식회사 휴온스랩 | 지속형 지방산-펩타이드 유도체 및 이의 용도 |
| KR20240145523A (ko) * | 2022-02-24 | 2024-10-07 | 엔테라 바이오 리미티드 | 글루카곤 유사 펩타이드-2의 경구 투여를 위한 산 중화 중합체를 포함하는 제형 |
| WO2024068933A1 (en) * | 2022-09-30 | 2024-04-04 | Zealand Pharma A/S | Glucagon-like-peptide-2 (glp-2) analogues and their medical uses for the treatment of short bowel syndrome (sbs) |
| WO2024156884A1 (en) | 2023-01-27 | 2024-08-02 | Zealand Pharma A/S | Glucagon-like-peptide-2 (glp-2) analogues and their medical uses for the treatment of short bowel syndrome (sbs) |
| CN116478269A (zh) * | 2023-04-28 | 2023-07-25 | 成都奥达生物科技有限公司 | 一种长效替度鲁肽化合物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| ES2427150T3 (es) * | 2004-11-01 | 2013-10-29 | Nps Pharmaceuticals, Inc. | Tratamiento de pacientes con el síndrome del intestino corto con colon en continuidad |
| EA014184B1 (ru) * | 2005-05-04 | 2010-10-29 | Зеаланд Фарма А/С | Аналоги глюкагонподобного пептида-2 (glp-2) |
| CN101331224A (zh) * | 2005-10-24 | 2008-12-24 | 森托科尔公司 | Glp-2模拟体、多肽、组合物、方法和用途 |
| JP5819586B2 (ja) * | 2006-11-08 | 2015-11-24 | ジーランド ファーマ アクティーゼルスカブ | 選択的グルカゴン様ペプチド−２（ｇｌｐ−２）類似体 |
| KR102007054B1 (ko) * | 2011-09-12 | 2019-08-02 | 아뮤닉스 파마슈티컬스, 인크. | 글루카곤-유사 펩티드-2 조성물 및 이의 제조 및 사용 방법 |
| KR20150006052A (ko) * | 2012-05-03 | 2015-01-15 | 질랜드 파마 에이/에스 | 글루카곤-유사 펩타이드-2 (ｇｌｐ-2) 유사체 |
| US20160067311A1 (en) * | 2014-09-10 | 2016-03-10 | Helsinn Healthcare Sa | Use of elsiglutide to treat gastrointestinal mucositis including chemotherapy-induced diarrhea |
| CN113710692A (zh) * | 2019-02-11 | 2021-11-26 | Opko生物科学有限公司 | 长效glp-2类似物 |
-
2018
- 2018-06-15 PE PE2019002548A patent/PE20200678A1/es unknown
- 2018-06-15 JP JP2020519850A patent/JP7200238B2/ja active Active
- 2018-06-15 DK DK18734135.9T patent/DK3638291T3/da active
- 2018-06-15 WO PCT/EP2018/065951 patent/WO2018229252A1/en active Application Filing
- 2018-06-15 SG SG11201912161SA patent/SG11201912161SA/en unknown
- 2018-06-15 CN CN201880053014.6A patent/CN111032072A/zh active Pending
- 2018-06-15 KR KR1020237006296A patent/KR20230035677A/ko not_active Application Discontinuation
- 2018-06-15 EP EP18734135.9A patent/EP3638291B1/en active Active
- 2018-06-15 EP EP21150552.4A patent/EP3881861B1/en active Active
- 2018-06-15 KR KR1020207001446A patent/KR102504200B1/ko active IP Right Grant
- 2018-06-15 DK DK21150552.4T patent/DK3881861T3/da active
- 2018-06-15 EP EP24182737.7A patent/EP4424362A2/en active Pending
- 2018-06-15 ES ES18734135T patent/ES2894629T3/es active Active
- 2018-06-15 TW TW107120806A patent/TWI791539B/zh active
- 2018-06-15 MX MX2019015054A patent/MX2019015054A/es unknown
- 2018-06-15 BR BR112019026711-5A patent/BR112019026711A2/pt unknown
- 2018-06-15 IL IL271245A patent/IL271245B2/en unknown
- 2018-06-15 AU AU2018285580A patent/AU2018285580B2/en active Active
- 2018-06-15 IL IL299864A patent/IL299864B2/en unknown
- 2018-06-15 CN CN202410762243.2A patent/CN118526577A/zh active Pending
- 2018-06-15 CA CA3066523A patent/CA3066523A1/en active Pending
-
2019
- 2019-07-15 US US16/511,766 patent/US20200000883A1/en active Pending
- 2019-12-12 CO CONC2019/0014028A patent/CO2019014028A2/es unknown
- 2019-12-13 ZA ZA2019/08355A patent/ZA201908355B/en unknown
- 2019-12-13 CL CL2019003660A patent/CL2019003660A1/es unknown
- 2019-12-13 MX MX2023003828A patent/MX2023003828A/es unknown
-
2022
- 2022-12-20 JP JP2022203265A patent/JP7566859B2/ja active Active
-
2024
- 2024-04-16 AU AU2024202486A patent/AU2024202486B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019014028A2 (es) | Posologías para la administración de análogos de péptido de tipo glucagon-2 (glp-2) | |
| MX2023010869A (es) | Polipéptidos selectivos del receptor de glucagón y métodos para utilizarlos. | |
| CO2019005924A2 (es) | Agonistas duales acilados de glp-1/glp-2 | |
| UY37505A (es) | Conjugados que comprenden un agonista dual de glp-1/glucagón, un conector y ácido hialurónico | |
| AR099569A1 (es) | Derivados de insulina y los usos médicos de estos | |
| AR106364A1 (es) | Derivados de insulina y sus usos médicos | |
| CL2023000087A1 (es) | Coagonistas de los receptores glp-1 y gip adecuados para el suministro oral | |
| CL2017002293A1 (es) | Tratamiento de pacientes con diabetes mellitus de tipo 2 | |
| RU2017120184A (ru) | Лекарства для замедления течения болезни паркинсона | |
| ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
| CL2017001843A1 (es) | Lixisenatida y/o una sal farmacéuticamente aceptable de la misma para el tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2. | |
| CL2020000270A1 (es) | Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf. | |
| CO2021004019A2 (es) | Vacunas peptídicas | |
| CL2023000090A1 (es) | Coagonistas de los receptores de glp-1 y gip | |
| DOP2019000072A (es) | Composición farmacéutica con antagonista del receptor de mineralocorticoides y su uso | |
| CO2020002500A2 (es) | Análogos de insulina acilados novedosos y usos de estos | |
| AR112109A1 (es) | Regímenes de dosificación para la administración de análogos de glucagón-péptido-2 (glp-2) | |
| AR111803A1 (es) | Derivado de ciclopentan[g]quinazolin-4-ona y su empleo en el tratamiento de cáncer resistente al platino | |
| UY31790A (es) | Utilización de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administración de dronedarona | |
| CO2022004947A2 (es) | Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente | |
| CL2018002765A1 (es) | Proceso de producción de formulaciones sólidas de mesalazina. | |
| Awan et al. | Toxicity study of piroxicam in broilers | |
| PH12018500889A1 (en) | Pharmaceutical preparation for delivery of porous material to large intestine or lower part of small intestine | |
| AR123039A1 (es) | Coagonistas de los receptores de glp-1 y gip | |
| GB201714203D0 (en) | Dosage regimes for the administration of Glucagon-Like Peptide-2(GLP-2)Analogues |